Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Analyst Comments: AtheroGenics, Toyota, Jamba, GlaxoSmithKline, Metabasis, AFLAC, Crown Castle, Epicor, Amylin Pharma, CNOOC, Skyworks, Tejon
Oct 02, 2008 08:33 AM
- Analyst Comments: Alexza Pharma, Abbott Lab, Metabasis, Quicksilver, ASM International
Jun 13, 2008 04:45 PM
- Pfizer completes $195 million Encysive acquisition and Metabasis Presents Preclinical Results for MB07803, Its Product Candidate for Type 2 Diabetes, and Its Glucagon Antagonist Program at the American Diabetes Association Meeting
Jun 10, 2008 11:29 AM
- Analyst Comments: deCODE, BorgWarner, Pride International, ChoicePoint, Metabasis Therapeutics, Owens Illinois, Cummins
May 02, 2008 02:42 PM
- Metabasis Therapeutics To Get $1.5 Million Over 1-Year Extension
Apr 23, 2008 09:33 AM
- Analyst Comments: Metabasis, Westell Technologies, MTG Investment, Allergan, Capella Education, Ford, NMS Communications
Mar 19, 2008 10:38 AM
- Seeking Visibility from Metabasis
Feb 20, 2008 10:02 AM
- Analyst Comments
Dec 27, 2007 02:20 AM
- After Plunge, MBRX Now a Hold
Sep 24, 2007 07:36 PM
- Thumping Thursday & Ominous Omens
Aug 10, 2007 09:58 AM
- Metabasis Therapeutics Announces Third Quarter 2008 Results and Recent Company Accomplishments and Announces Restructuring of Operations
Nov 12, 2008 08:01 PM
- Metabasis Therapeutics Reschedules Third Quarter 2008 Results and Conference Call
Nov 04, 2008 04:30 PM
- Results from Metabasis' Phase 2a Clinical Trial for MB07803 Show Statistically Significant Reductions in FPG, as Well as Safety and Tolerability
Nov 03, 2008 08:59 AM
- Metabasis to Present at Four Upcoming Healthcare Investor Conferences
Oct 22, 2008 09:16 AM
- Metabasis Announces Conference Call and Live Webcast to Discuss Third Quarter 2008 Financial Results
Oct 10, 2008 11:53 AM
- Metabasis Therapeutics Announces Initiation of a Clinical Trial for MB07803, Its Novel Product Candidate for the Treatment of Type 2 Diabetes
Sep 23, 2008 04:04 PM
- Metabasis Therapeutics Appoints Dr. Molly Holman as Vice President of Intellectual Property
Sep 09, 2008 09:17 AM
- Metabasis Therapeutics Announces Second Quarter 2008 Results and Comments on Recent Significant Company Accomplishments
Aug 07, 2008 04:22 PM
- Metabasis Therapeutics Announces Collaboration with Roche to Develop Liver-Targeted Compounds for the Treatment of Hepatitis C
Aug 07, 2008 04:04 PM
- Metabasis' Results from Its Phase 2a Clinical Trial for MB07803 to Be Presented at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension
Jul 29, 2008 04:01 PM
- Form 4 METABASIS THERAPEUTICS For: Nov 18 Filed by: Laikind Paul K (10K)
Nov 19, 2008 08:11 PM
- Form 4 METABASIS THERAPEUTICS For: Nov 12 Filed by: Gumbiner Barry (10K)
Nov 13, 2008 02:03 PM
- Form 4 METABASIS THERAPEUTICS For: Sep 26 Filed by: Millican Trisha (10K)
Sep 30, 2008 05:18 PM
- Form 4 METABASIS THERAPEUTICS For: Aug 04 Filed by: Foyt Howard (10K)
Aug 06, 2008 12:33 PM
- Form 4 METABASIS THERAPEUTICS For: Aug 04 Filed by: Millican Trisha (10K)
Aug 06, 2008 12:32 PM
- Form 4 METABASIS THERAPEUTICS For: Aug 04 Filed by: Erion Mark D (10K)
Aug 06, 2008 12:31 PM
- Form 4 METABASIS THERAPEUTICS For: Aug 04 Filed by: Baracchini Edgardo Jr (10K)
Aug 06, 2008 12:30 PM
- Form 4 METABASIS THERAPEUTICS For: Jun 10 Filed by: EVNIN LUKE (10K)
Jun 12, 2008 08:22 PM
- Form 4 METABASIS THERAPEUTICS For: Jun 10 Filed by: BURGESS DANIEL D (10K)
Jun 11, 2008 07:04 PM
- Form 4 METABASIS THERAPEUTICS For: Jun 10 Filed by: HALE DAVID F (10K)
Jun 11, 2008 07:04 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
MBRX
|
Compare to S&P
|
| YTD |
-84.28 %
|
-0.01 %
|
| 4 Weeks |
-46.59 %
|
-36.77 %
|
| 12 Weeks |
-68.87 %
|
-51.65 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 17.65 %
|
|
EPS Growth in Last Year: 17.65 %
|
|
Sales Growth in Last Quarter: 104.08 %
|
|
Sales Growth in Last Quarter: -47.15 %
|
|
|
